Analysis and ethical discussion of the whole process of three-generation IVF combined with surrogate births
Synergistic effect of three-generation IVF technology and surrogacy Three-generation IVF (Preimplantation Genetic Testing, PGT) combined with surrogacy offers the possibility of having healthy offspring to those who are unable to conceive on their own (e.g., uterine dysfunction, carriers of severe genetic diseases). This model requires strict adherence to medical norms and ethical guidelines, and its core process is divided into three major stages: embryo screening, surrogate matching, and transfer and pregnancy management. The core process of three-generation IVF surrogacy Ovulation Promotion and Embryo Cultivation: Women receive ovulation promotion treatment to obtain eggs, which are formed into embryos through in vitro fertilization (IVF) or intracytoplasmic single sperm injection (ICSI) and cultured to the blastocyst stage on day 5-6.Embryo biopsy and testing: 3-5 cells are extracted from the blastocyst trophoblast for genetic analysis, including screening for chromosomal aneuploidy (PGT-A), monogenic disorders (PGT-M) and chromosomal structural abnormalities (PGT-SR). Healthy embryos are frozen and preserved, and abnormal embryos are eliminated. Surrogate screening: Surrogate mothers need to meet the requirements of age (21-40 years old), BMI (18.5-30), healthy reproductive history, and pass infectious disease, genetic disease and psychological assessment.Endometrial conditioning: Surrogates need to optimize the endometrial thickness to 8-12 mm through hormone therapy (e.g. progesterone) to ensure the environment for embryo implantation. Thawing and transferring: Selected healthy embryos are thawed and transferred to the uterus of the surrogate, after which luteal support is provided to maintain pregnancy.Prenatal diagnosis and follow-up: NT screening at 12 weeks of pregnancy, confirmation of fetal genetic health by amniocentesis at 18-24 weeks, long-term follow-up of maternal and infant health is required after delivery. Applicable groups and medical value Families with genetic diseases: such as carriers of single-gene diseases such as thalassemia and hemophilia, the transmission of the disease can be blocked by PGT-M.People with chromosomal abnormalities: patients with structural abnormalities…
